COLL director exercises options for 8,700 shares

COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of Common Stock at $16.49 per share.

Accepted by SEC EDGAR 06/10/2026 - 04:10 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of Common Stock at $16.49 per share. These options were fully vested and exercisable. After the transaction, Santini directly holds 112,483 shares of Common Stock, and the exercised option covering 8,700 shares is fully used.

Insider Trade Summary

8,700 shares exercised/converted

Exercise 2 txns

Insider SANTINI GINO

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Purchase)	8,700	$0.00	$0.00
Exercise	Common Stock	8,700	$16.49	$143K

Holdings After Transaction: Stock Option (Right to Purchase) — 0 contracts (Direct); Common Stock — 112,483 shares (Direct)

Holdings Before and After: Stock Option (Right to Purchase), 8,700 to 0 contracts (Direct); Common Stock, 103,783 to 112,483 shares (Direct)

Footnotes (1)

F1. The option is fully vested and exercisable.

Key Figures

Shares acquired via exercise: 8,700 shares Exercise price: $16.49 per share Shares held after transaction: 112,483 shares +1 more

4 metrics

Shares acquired via exercise 8,700 shares Common Stock acquired through option exercise on 2026-06-08

Exercise price $16.49 per share Stock Option (Right to Purchase) conversion price

Shares held after transaction 112,483 shares Direct Common Stock ownership following the exercise

Exercised option shares remaining 0 shares Stock option covering 8,700 shares fully exercised

Key Terms

Stock Option (Right to Purchase), Exercise or conversion of derivative security, Common Stock, fully vested and exercisable

4 terms

Stock Option (Right to Purchase) financial

"security_title: "Stock Option (Right to Purchase)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

fully vested and exercisable financial

"The option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did COLLEGIUM PHARMACEUTICAL (COLL) director Gino Santini report?

Director Gino Santini reported exercising stock options to acquire 8,700 shares of COLLEGIUM PHARMACEUTICAL Common Stock at $16.49 per share. This transaction converts a derivative award into directly held shares without any reported open-market sale.

How many COLL shares does Gino Santini hold after this Form 4 transaction?

After exercising options, Gino Santini directly holds 112,483 shares of COLLEGIUM PHARMACEUTICAL Common Stock. This figure reflects his post-transaction ownership reported in the Form 4 and shows his continuing equity stake in the company.

What was the exercise price of Gino Santini’s COLLEGIUM PHARMACEUTICAL stock options?

The exercised stock options had a conversion or exercise price of $16.49 per share. Exercising at this fixed price turns the option grant into 8,700 shares of COLLEGIUM PHARMACEUTICAL Common Stock that Santini now holds directly.

Were any COLLEGIUM PHARMACEUTICAL shares sold in this Form 4 transaction?

No share sales were reported. The Form 4 shows a derivative exercise labeled as an acquisition, with 8,700 shares of Common Stock received and no open-market sale, gift, or tax-withholding disposition reported in the transaction summary.

What happened to Gino Santini’s COLLEGIUM PHARMACEUTICAL stock option position?

The stock option covering 8,700 shares of COLLEGIUM PHARMACEUTICAL Common Stock now shows zero derivative shares remaining after exercise. This indicates the option grant tied to this transaction has been fully exercised and is no longer outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SANTINI GINO

(Last)

(First)

(Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON

MASSACHUSETTS

02072

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2026		M		8,700	A	$16.49	112,483	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Purchase)	$16.49	06/08/2026		M			8,700	⁽¹⁾	06/09/2026	Common Stock	8,700	$0	0	D

Explanation of Responses:

1. The option is fully vested and exercisable.

	/s/ Colleen Tupper as Attorney-in-Fact for Gino Santini	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR